Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

University of California San Francisco Health, San Francisco, California, United States

University of Colorado Cancer Center, Aurora, Colorado, United States

Advent Health Hematology and Oncology, Orlando, Florida, United States

University of Iowa, Iowa City, Iowa, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Henry Ford Health, Detroit, Michigan, United States

Regents of the University of Minnesota, Minneapolis, Minnesota, United States

Washington University, School of Medicine, St Louis, Missouri, United States

Ichan School of Medicine at Mount Sinai, New York, New York, United States

Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States

Henry-Joyce Cancer Clinic, The Vanderbilt Clinic, Nashville, Tennessee, United States

MD Anderson Cancer Center, Houston, Texas, United States

Northwest Medical Specialties, Tacoma, Washington, United States

Macquarie Health, Sydney, New South Wales, Australia

Breast Cancer Research Center- Western Australia, Nedlands, Western Australia, Australia